Incoming and outgoing links Eosinophilic pustular folliculitis
Back to articleIncoming links
- Betamethasone valerate cream hydrophilic 0.025/0.05 or 0.1% (nrf 11.37.)
- Betamethasone valerate emulsion hydrophilic 0,025/0,05 or 0,1 % (nrf 11.47.)
- Candida folliculitis
- Clioquinol lotio 0.5-5%
- Dermatitis cruris pustulosa et atrophicans
- Eosinophilia and skin
- Eosinophilic pustular folliculitis
- Eosinophilic pustulous folliculitis of childhood
- Eosinophil pustular folliculitis
- Eosinophil pustulose
- Erosive pustular dermatosis of the scalp
- Folliculitis eosinophilic pustular
- Granulocyte eosinophile
- Hydrocortisone cream 0.5-2.0% (w/o)
- Immune reconstruction syndrome
- Milia of the infant
- Newborns, skin changes
- Ofuji syndrome
- Spongiosis, eosinophilic
- Sterile eosinophilic pustulose
- Triamcinolone acetonide cream hydrophilic 0,025/0,05/0,1% (nrf 11.38.)
- Zinc oxide shaking mixture ethanol-containing skin-coloured (nrf 11.3.)
Outgoing links
- Abt-letterer-siwe disease
- Allopurinol
- Antihistamines
- Betamethasone valerate
- Betamethasone valerate cream hydrophilic 0.025/0.05 or 0.1% (nrf 11.37.)
- Betamethasone valerate emulsion hydrophilic 0,025/0,05 or 0,1 % (nrf 11.47.)
- Calcineurin inhibitors
- Candidoses
- Carbamazepine
- Cart
- Ciclosporin a
- Clioquinol lotio 0.5-5%
- Dadps
- Dermatitis herpetiformis
- Desloratadine
- Eosinophilia and skin
- Erythema multiforme, minus-type
- Erythema neonatorum
- Glucocorticosteroids
- Glucorticosteroids topical
- Hiv infection
- Hydrocortisone
- Hydrocortisone cream 0.5-2.0% (w/o)
- Impetigo (overview)
- Incontinentia pigmenti (Bloch-Sulzberger)
- Itraconazole
- Larva migrans
- Levocetirizine
- Metronidazole
- Miliaria pustulosa
- Permethrin
- Pseudopélade
- Psoriasis pustulosa
- Pustule
- Puva therapy
- Skabies
- Spongiosis
- Sulfones
- Tacrolimus
- Tinea capitis (overview)
- Transient neonatal pustular Melanosis
- Triamcinolone acetonide cream hydrophilic 0,025/0,05/0,1% (nrf 11.38.)
- Zinc oxide shaking mixture ethanol-containing skin-coloured (nrf 11.3.)